

Publikationsverzeichnis:	
lfd. Nr.	
1	Al-Ali HK , Griesshammer M, le Coutre P, Waller CF, Liberati AM, Schafhausen P, Tavares R, Giraldo P, Foltz L, Raanani P, Gupta V, Tannir B, Perez Ronco J, Ghosh J, Martino B, Vannucchi AM. Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial. <i>Haematologica</i> . 2016 May 31. [Epub ahead of print]
2	Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK , Gisslinger H, Knoops L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovska V, Gopalakrishna P, Barbui T. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. <i>Leukemia</i> . 2016;30(8):1701-7.
3	Al-Ali HK , Vannucchi AM. Managing patients with myelofibrosis and low platelet counts. <i>Ann Hematol</i> . 2016 May 21. [Epub ahead of print]
4	Al-Ali HK , Stalbovska V, Gopalakrishna P, Perez-Ronco J, Foltz L. Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis. <i>Leuk Lymphoma</i> . 2016; 57(10):2464-7.
5	Kahl C, Krahl R, Becker C, Al-Ali HK , Sayer HG, Schulze A, Herold M, Hänel M, Scholl S, Hochhaus A, Uharek L, Maschmeyer G, Haehling D, Junghanß C, Peter N, Kämpfe D, Kettner E, Heinicke T, Fischer T, Kreibich U, Wolf HH, Niederwieser D. Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). <i>J Cancer Res Clin Oncol</i> . 2016;142(1):305-15.
6	Pfrepper C, Klink A, Behre G, Schenk T, Franke GN, Jentzsch M, Schwind S, Al-Ali HK , Hochhaus A, Niederwieser D, Sayer HG. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation. <i>J Cancer Res Clin Oncol</i> . 2016;142(1):317-24.
7	Jaekel N, Lieder K, Albrecht S, Leismann O, Hubert K, Bug G, Kröger N, Platzbecker U, Stadler M, de Haas K, Altamura S, Muckenthaler MU, Niederwieser D, Al-Ali HK . Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplant</i> . 2016;51(1):89-95.
8	Niederwieser C, Starke S, Fischer L, Krahl R, Beck J, Gruhn B, Ebell W, Körholz D, Wößmann W, Bader P, Lang P, Al-Ali HK , Cross M, Eisfeld AK, Heyn S, Vucinic V, Franke GN, Lange T, Pönisch W, Behre G, Christiansen H. Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations. <i>Ann Hematol</i> . 2016;95(3):473-81.
9	Koehler A, Hubert K, Lange T, Siebolts U, Wickenhauser C, Gopalakrishna P, Niederwieser D, Monecke A, Al-Ali HK . JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. <i>Ann Hematol</i> . 2015;94(11):1929-30.
10	McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovska V, Recher C, Theunissen K, Gisslinger H, Kiladjian JJ, Al-Ali HK . The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. <i>Exp Hematol Oncol</i> . 2015;15;4:26.
11	Wang SY, Ebert T, Jaekel N, Schubert S, Niederwieser D, Al-Ali HK . Miliary tuberculosis after initiation of ibrutinib in chronic lymphocytic leukemia. <i>Ann Hematol</i> . 2015; 94(8):1419-20.

12	Poenisch W, Plötze M, Holzvogt B, Andrea M, Schliwa T, Zehrfeld T, Hammerschmidt D, Schwarz M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Gutsche K, Reifenrath K, Schwarzbach H, Heyn S, Franke GN, Jentzsch M, Leiblein S, Schwind S, Lange T, Vucinic V, AI-Ali HK , Niederwieser D. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma. <i>J Cancer Res Clin Oncol</i> . 2015;141(11):2013-22.
13	Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Bernal Del Castillo T, AI-Ali HK , Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Döhner H. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. <i>Blood</i> 2015; 126(3):291-9.
14	Rockstroh A, AI-Ali HK , Lange T, Pönisch W, Krahl R, Cross M, Behre G, Niederwieser D, Pfrepper C. Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation. <i>J Cancer Res Clin Oncol</i> . 2015; 141(12):2193-203
15	Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, AI-Ali HK . Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. <i>Bone Marrow Transplant</i> . 2014;49(2):179-84.
16	Platzbecker U, AI-Ali HK , Gattermann N, Haase D, Janzen V, Krauter J, Götze K, Schlenk R, Nolte F, Letsch A, Ottmann OG, Kündgen A, Lübbert M, Germing U, Wermke M, Reinhard H, Weiss C, Lieder K, Ehninger G, Leismann O, Giagounidis A. Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients. <i>Leukemia</i> . 2014;28(3):696-8.
17	AI-Ali HK , Jaekel N, Niederwieser D. The role of hypomethylating agents in the treatment of elderly patients with AML. <i>J Geriatr Oncol</i> . 2014;5(1):89-105.
18	Mesa RA, Kiladjian JJ, Verstovsek S, AI-Ali HK , Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> . 2014;99(2):292-8.
19	Harrison C, Mesa R, Kiladjian JJ, AI-Ali HK , Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy R, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi A. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>Br J Haematol</i> . 2013;162(2):229-39
20	Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, AI-Ali HK , Jäkel N, Niederwieser D. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077. <i>Br J Haematol</i> . 2013;162(2):202-9
21	Pönisch W, Moll B, Bourgeois M, Andrea M, Schliwa T, Heyn S, Schmalfeld M, Edelmann T, Becker C, Hoffmann FA, Schwarzer A, Kreibich U, Egert M, Stiegler R, Krahl R, Remane Y, Bachmann A, Lindner T, Weidhase L, Petros S, Fricke S, Vucinic V, AI-Ali H , Niederwieser D. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with relapsed or refractory multiple myeloma and light chain-induced renal failure. <i>J Cancer Res Clin Oncol</i> . 2013;139(11):1937-46.

22	Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK , Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoop L, Gisslinger H; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. <i>Blood</i> . 2013;122(25):4047-53.
23	Cross M, Bach E, Tran T, Krahl R, Jaekel N, Niederwieser D, Junghanss C, Maschmeyer G, Al-Ali HK . Pre-treatment LINE-1 methylation levels, not early hypomethylation under treatment, predict haematological response to azacitidine in elderly patients with acute myeloid leukaemia. <i>OncoTargets and Therapy</i> 2013; 6:741-8.
24	Pönisch W, Heyn S, Beck J, Wagner I, Mohren M, Hoffmann FA, Lange T, Schmalfeld M, Zehrfeld T, Schwarzer A, Winkelmann C, Edelmann T, Röhrborn R, Hebenstreit K, Al-Ali HK , Jäkel N, Niederwieser D. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077 . <i>Br J Haematol</i> . 2013;162(2):202-9.
25	Pönisch W, Bourgeois M, Moll B, Heyn S, Jäkel N, Wagner I, Rohrberg R, Hurtz HJ, Schmalfeld M, Aßmann M, Edelmann T, Mohren M, Hoffmann FA, Becker C, Schwarzer A, Schönfelder U, Zehrfeld T, Hensel G, Lösckke K, Krahl R, Al Ali H , Niederwieser D. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. <i>Journal of Cancer Research and Clinical Oncology</i> . <i>J Cancer Res Clin Oncol</i> . 2013;139(3):499-508.
26	Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK , Wolf HH, Herbst R, Maschmeyer G, Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S, Kirsch M, Montemurro M, Krüger WH, Dölken G; Ostdeutsche Studiengruppe Hämatologie und Onkologie. Long-term follow-up of high-dose chemotherapy with autologous stem-cell transplantation and response-adapted whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II study. <i>Ann Oncol</i> . 2012;23(7):1809-12.
27	Tschiedel S, Bach E, Jilo A, Wang SY, Lange T, Al-Ali HK , Vucinic V, Niederwieser D, Cross M. Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia. <i>Leuk Lymphoma</i> . 2012;53(8):1569-76.
28	Harrison C, Kiladjian JJ, Al-Ali HK , Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoop L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>N Engl J Med</i> . 2012;366(9):787-98.
29	Bach E, Krahl R, Lange T, Schüler F, Al-Ali H , Büchner T, Haferlach T, Dölken G, Niederwieser D, Cross M. Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia. <i>Leuk Lymphoma</i> . 2012;53(8):1561-8.
30	Al-Ali HK , Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Hoppe G, Niederwieser D. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. <i>Leuk Lymphoma</i> . 2012;53(1):110-7.
31	Eisfeld AK, Krahl R, Jaekel N, Niederwieser D, Al-Ali HK . Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation. <i>Am J Blood Res</i> . 2012;2(4):243-53.
32	Al-Ali HK , Bourgeois M, Krahl R, Edel E, Leiblein S, Poenisch W, Basara N, Lange T, Niederwieser D. The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplant</i> . 2011;46(10):1296-302.

33	Eisfeld A-K, Westerman M, Krahl R, Leiblein S, Liebert UG, Hehme M, Teupser D, Niederwieser D, Al-Ali HK . Highly elevated serum hepcidin in patients with acute myeloid leukemia prior to and after allogeneic hematopoietic cell transplantation: Does this protect from excessive parenchymal iron loading?. <i>Adv Hematol</i> . 2011;49:1058
34	de Hosson LD, van de Warrenburg BP, Preijers FW, Blijlevens NM, van der Reijden BA, Kremer HP, Lefeber DJ, Allebes WA, Al-Ali H , Niederwieser DW, Schaap NP, Schattenberg AV. Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. <i>Bone Marrow Transplant</i> . 2011;46(8):1071-6
35	Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, Leiblein S, Al-Ali HK , Edelmann J, Thiery J, Niederwieser D. Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. <i>Leukemia</i> . 2011;25(3):498-505.
36	Fangmann J, Al-Ali HK , Sack U, Kamprad M, Tautenhahn HM, Faber S, Hauss J, Niederwieser D, Lindner T, Bachmann A. Kidney transplant from the same donor without maintenance immunosuppression after previous hematopoietic stem cell transplant. <i>Am J Transplant</i> . 2011;11(1):156-62
37	Edel E, Al-Ali HK , Seeger S, Kauschat D, Matthes G. Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience. <i>Transfus Med Hemother</i> . 2010;37(1):13-19.
38	Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, Lange T, Simon JC, Niederwieser D, Al-Ali HK . UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. <i>Bone Marrow Transplant</i> . 2010;45(12):1741-8
39	Al-Ali H , Cross M, Lange T, Freund M, Dölken G, Niederwieser D. Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia. <i>Curr Opin Oncol</i> . 2009;21 Suppl 1:17-22.
40	Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N, Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer HG, Al-Ali H , Kamprad F, Niederwieser D; East German Study Group Hematology and Oncology (OSHO). Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. <i>Leukemia</i> . 2009;23(4):635-40.
41	Bartsch K, Al-Ali H , Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C. Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used. <i>Transplantation</i> . 2009;87(2):217-21.
42	Avivi I, Montoto S, Canals C, Maertens J, Al-Ali H , Mufti GJ, Finke J, Schattenberg A, Fanin R, Cornelissen JJ, Vernant JP, Russell N, Beguin Y, Thomson K, Verdonck LF, Kobbe G, Tilly H, Socié G, Sureda A; EBMT Lymphoma Working Party. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Br J Haematol</i> . 2009;147(5):719-28.
43	Schlaak M, Treudler R, Colsman A, Al-Ali H , Simon JC. Oral graft-versus-host disease: successful therapy with extracorporeal photopheresis and topical tacrolimus. <i>J Eur Acad Dermatol Venereol</i> . 2008;22(1):112-3
44	Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK , Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D. Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality. <i>Acta Haematol</i> . 2008;119(2):111-4.
45	Pelz-Ackermann O, Cross M, Pfeifer H, Deininger M, Wang SY, Al-Ali HK , Niederwieser D, Lange T. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. <i>Leukemia</i> . 2008;22(12):2288-91.

46	Montemurro M, Kiefer T, Schüler F, Al-Ali HK , Wolf HH, Herbst R, Haas A, Helke K, Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. <i>Ann Oncol</i> . 2007;18(4):665-71.
47	Schaich M, Schlenk RF, Al-Ali HK , Döhner H, Ganser A, Heil G, Illmer T, Krahl R, Krauter J, Sauerland C, Büchner T, Ehninger G. Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> . 2007;92(6):763-70.
48	Herold M, Haas A, Srock S, Nesper S, Al-Ali HK , Neubauer A, Dölken G, Naumann R, Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group Hematology and Oncology Study. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. <i>J Clin Oncol</i> . 2007;25(15):1986-92.
49	Al-Ali HK , Brand R, van Biezen A, Finke J, Boogaerts M, Fauser AA, Egeler M, Cahn JY, Arnold R, Biersack H, Niederwieser D, de Witte T. A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Leukemia</i> . 2007;21(9):1945-51.
50	Al-Ali HK , Wittekind C, Niederwieser D. Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab. <i>Dtsch Med Wochenschr</i> . 2007;132(33):1688-91.
51	Niederwieser D, Lange T, Cross M, Basara N, Al-Ali H . Reduced intensity conditioning (RIC) haematopoietic cell transplants in elderly patients with AML. <i>Best Pract Res Clin Haematol</i> . 2006;19(4):825-38.
52	Koch CA, Gimm O, Vortmeyer AO, Al-Ali HK , Lamesch P, Ott R, Kluge R, Bierbach U, Tannapfel A. Does the expression of c-kit (CD117) in neuroendocrine tumors represent a target for therapy? <i>Ann N Y Acad Sci</i> . 2006;1073:517-26.
53	Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H, Cordonnier C, Rio B, Gratwohl A, Lange T, Al-Ali H , Storer B, Maloney D, McSweeney P, Chauncey T, Agura E, Bruno B, Maziarz RT, Petersen F, Storb R. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>J Clin Oncol</i> . 2006;24(3):444-53.
54	Then Bergh F, Niklas A, Strauss A, von Ahsen N, Niederwieser D, Schwarz J, Wagner A, Al-Ali HK . Rapid progression of Myelodysplastic syndrome to acute myeloid leukemia on sequential azathioprine, IFN-beta and copolymer-1 in a patient with multiple sclerosis. <i>Acta Haematol</i> . 2006;116(3):207-10.
55	Niederwieser D, Gentilini C, Hegenbart U, Lange T, Becker C, Wang SY, Bartsch K, Pönisch W, Raida M, Al-Ali H . Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias. <i>Crit Rev Oncol Hematol</i> . 2005;56(2):275-81.
56	Kerbauf FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK , Radich J P, Maloney DG, Agura E, Bruno B, Epner EM, Chauncey T R, Blume KG, Niederwieser D, Sandmaier BM. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. <i>Leukemia</i> . 2005;19(6):990-7.

57	Sorrer ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H , Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. <i>J Clin Oncol</i> . 2005;23(16):3819-29.
58	Lange T, Bumm T, Mueller M, Otto S, Al-Ali HK , Grommisch L, Musiol S, Franke C, Krahl R, Niederwieser D, Deininger MW. Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation. <i>Leukemia</i> . 2005;19(7):1262-5.
59	Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK . Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. <i>Bone Marrow Transplant</i> . 2005;35(5):515-9
60	Al-Ali HK , Heinrich MC, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D, Druker B, Deininger M. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. <i>The Hematology Journal</i> 2004; 5(1):55-60.
61	Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, Köhler T, Krahl R, Niederwieser D, Deininger M. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. <i>Haematologica</i> 2004; 89(1):49-57.
62	Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H , Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. <i>Leukemia</i> 2004; 18(9):1468-75.
63	Bumm T, Müller C, Al-Ali HK , Krohn K, Shepherd P, Schmidt E, Leiblein S, Franke C, Hennig E, Friedrich T, Krahl R, Niederwieser D, Deininger M. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. <i>Blood</i> 2003; 101(5):1941-9
64	Bredt M, Schönfeld G, Kleeberger W, König E, Kröning H, Kettner E, Al-Ali HK , Niederwieser D. Late-onset Epstein-Barr virus (EBV)-negative extranodal B-precursor lymphoblastic lymphoma of donor origin after hematopoietic stem cell transplantation (HSCT). <i>Bone Marrow Transplantation</i> 2003; 31(11):1071-2.
65	Al-Ali HK , Leiblein S, Kovacs I, Hennig E, Niederwieser D, Deininger M. CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall. <i>Blood</i> . 2002;100(3):1092-1092.